ArticleScientific reports2024
Distant metastasis patterns among lung cancer subtypes and impact of primary tumor resection on survival in metastatic lung cancer using SEER database.
Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Vasculopathy as a mechanical barrier to cancer spread: Clinical evidence and a rheology-based model in lung cancer and other solid tumors.Translational oncology · 2026Article
- Reprogramming resistance in advanced lung cancer: epigenetic modulation to restore therapeutic vulnerability.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- Survival trends in extensive-stage small cell lung cancer in the pre-immunotherapy and immunotherapy eras: a population-based SEER study.Journal of thoracic disease · 2026Article
- Survival by Detection Pathway in Patients With Lung Cancer-A Nationwide Descriptive Epidemiological Study in Japan.International journal of cancer · 2026Article
- Real-world effectiveness of pembrolizumab for first-line treatment of metastatic non-small-cell lung cancer: a decade of evidence and experience.Future oncology (London, England) · 2026Review
- Impact of Surgical Resection on 5-Year Survival in Elderly NSCLC Patients: A SEER Database Analysis With Machine Learning-Based Predictive Modeling in Patients Aged ≥ 60 (2000-2021).Cancer medicine · 2026Article
- Article
- Resection of Primary Lung Tumors in Patients with Stage IV EGFR-Mutant Lung Adenocarcinoma before Progression under First-Line TKI Treatment and Its Impact on Prognosis.Annals of surgical oncology · 2026Article
- Methylation signatures distinguish non-small cell lung cancer subtypes and are associated with survival in smokers with lung squamous cell carcinoma.Journal of the National Cancer Institute · 2026Article
- Systematic review and meta-analysis of AI in lung cancer metastasis imaging for diagnosis and prognosis.NPJ digital medicine · 2026Article
- Development and validation of nomograms for predicting overall survival and cancer-specific survival in female gastric signet-ring cell carcinoma: a SEER database analysis.Translational cancer research · 2026Article
- Imperatorin: A Furanocoumarin with Potential in Combating Cancer Development and Progression-A Comprehensive Review.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Development and validation of a machine-learning-based triage model incorporating systemic inflammatory, nutritional, coagulation, and tumor marker parameters for identifying baseline distant metastasis in lung cancer.Frontiers in oncology · 2026Article
- Review
- Histopathological and Molecular Predictors of the First Site of Dissemination in Non-Small Cell Lung Cancer.Current oncology (Toronto, Ont.) · 2025Article
- Characteristics of patients with non-small cell lung cancer and either limited or extensive synchronous metastatic spread in Germany-a population-based cancer registry cohort study.Translational lung cancer research · 2025Article
- Rectal metastasis as the initial presentation of primary lung adenocarcinoma with an EGFR L858R mutation: a case report.World journal of surgical oncology · 2025Article
- Site-Specific Inflammatory Signatures in Metastatic NSCLC: Insights from Routine Blood Count Parameters.Medicina (Kaunas, Lithuania) · 2025Article
- Lung metastases.Nature reviews. Disease primers · 2025Review
- [A Case of Endometrial Metastasis in Lung Adenocarcinoma after EGFR-TKIs Treatment Failure and Literature Review].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This research aimed to systematically uncover the metastatic characteristics and survival rates of lung cancer subtypes and to evaluate the impact of surgery at the primary tumor site on cancer-specific survival in DM lung cancer. We used the Surveillance, Epidemiology, and End Results (SEER) database (2010-2019) to identify primary lung cancers with DM at presentation (M1). Kaplan-Meier (KM) survival curves were generated and compared utilizing log-rank tests. Cox regression methods were employed to determine hazard ratios (HR) and 95% confidence intervals related to CSS factors. Inverse probability of treatment weighting (IPTW) was applied to reduce bias. We analyzed 77,827 M1 lung cancer cases, with 41.22% having DM at presentation. Bone metastasis was most common in ADC, ASC, SCC, LCC; brain in LCNEC; liver in SCLC. Lung was common in TC + AC and SCC. Long-term survival was best in TC + AC and worst in SCLC (p < 0.001). Male gender, age < 50, primary tumor site (main bronchus, lower lobe), large tumor diameter, ADC/SCLC/SCC pathology, and regional lymph node involvement were significant risk factors for multiorgan metastasis. Age ≥ 50, male, large tumor diameter, positive lymph nodes, and multiorgan metastases were associated with lower CSS. In contrast, radiotherapy, chemotherapy, systemic therapy, and surgery were associated with higher CSS rates. Primary tumor resection improved survival in lung cancer patients (excluding small cell lung cancer, SCLC) with single organ metastases (KM log rank p < 0.001, HR = 0.6165; 95% CI (0.5468-0.6951)), especially in brain (p < 0.001, HR = 0.6467; 95% CI (0.5505-0.7596)) and bone (p = 0.182, HR = 0.6289; p < 0.01), but not in liver or intrapulmonary metastases after IPTW. Significant differences in DM patterns and corresponding survival rates exist among lung cancer subtypes. Primary tumor resection improves survival in lung cancer patients (excluding small cell lung cancer, SCLC) with single organ metastases, with better outcomes in patients with brain and bone metastases, while no significant benefit was seen in patients with liver and intrapulmonary metastases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.